V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections
Conditions
Bacterial Infections, Virus Diseases
Trial Timeline
May 26, 2011 → Mar 13, 2013
NCT ID
NCT01341639About V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™
V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™ is a phase 3 stage product being developed by Merck for Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01341639. Target conditions include Bacterial Infections, Virus Diseases.
What happened to similar drugs?
18 of 20 similar drugs in Bacterial Infections were approved
Approved (18) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01341639 | Phase 3 | Completed |
Competing Products
20 competing products in Bacterial Infections